The DOI matches its Crossref record; 93 of the 97 references it cites were found in a registry or an index.
Bladder Cancer: A Review
Abstract
IMPORTANCE: Bladder cancer is a common malignancy in women and is the fourth most common malignancy in men. Bladder cancer ranges from unaggressive and usually noninvasive tumors that recur and commit patients to long-term invasive surveillance, to aggressive and invasive tumors with high disease-specific mortality. OBSERVATIONS: Advanced age, male sex, and cigarette smoking contribute to the development of bladder cancer. Bladder tumors can present with gross or microscopic hematuria, which is evaluated with cystoscopy and upper tract imaging depending on the degree of hematuria and risk of malignancy. Non-muscle-invasive tumors are treated with endoscopic resection and adjuvant intravesical therapy, depending on the risk classification. Enhanced cystoscopy includes technology used to improve the detection of tumors and can reduce the risk of recurrence. Patients with high-risk non-muscle invasive tumors that do not respond to adjuvant therapy with the standard-of-care immunotherapy, bacille Calmette-Guérin (BCG), constitute a challenging patient population to manage and many alternative therapies are being studied. For patients with muscle-invasive disease, more aggressive therapy with radical cystectomy and urinary diversion or trimodal therapy with maximal endoscopic resection, radiosensitizing chemotherapy, and radiation is warranted to curb the risk of metastasis and disease-specific mortality. Treatment of patients with advanced disease is undergoing rapid changes as immunotherapy with checkpoint inhibitors, targeted therapies, and antibody-drug conjugates have become options for certain patients with various stages of disease. CONCLUSIONS AND RELEVANCE: Improved understanding of the molecular biology and genetics of bladder cancer has evolved the way localized and advanced disease is diagnosed and treated. While intravesical BCG has remained the mainstay of therapy for intermediate and high-risk non-muscle-invasive bladder cancer, the therapeutic options for muscle-invasive and advanced disease has expanded to include immunotherapy with checkpoint inhibition, targeted therapies, and antibody-drug conjugates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A.-C., Boyd, S., Skinner, E., Bochner, B., Thangathurai, D., Mikhail, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.666 · Cited by 3,530
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., White, R. W. D., Sarosdy, M. F., Wood, D. P., Raghavan, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022148 · Cited by 2,668
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E. M., Cowan, N. C., Gakis, G., Hernández, V., Linares Espinós, E., Lorch, A., Neuzillet, Y., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.03.055 · Cited by 2,017
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Babjuk, M., Burger, M., Capoun, O., Cohen, D., Compérat, E. M., Dominguez Escrig, J. L., Gontero, P., Liedberg, F., Masson-Lecomte, A., Mostafid, A. H., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.08.010 · Cited by 1,615
Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
Chang, S. S., Boorjian, S. A., Chou, R., Clark, P. E., Daneshmand, S., Konety, B. R., Pruthi, R. S., Quale, D. Z., Ritch, C. R., Seigne, J. D., et al. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.06.049 · Cited by 1,509
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Shabsigh, A., Korets, R., Vora, K. C., Brooks, C. M., Cronin, A. M., Savage, C., Raj, G., Bochner, B. H., Dalbagni, G., Herr, H. W., et al. (2009) · European Urology · doi:10.1016/j.eururo.2008.07.031 · Cited by 1,400
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,333
Association Between Smoking and Risk of Bladder Cancer Among Men and Women
Freedman, N. D. (2011) · JAMA · doi:10.1001/jama.2011.1142 · Cited by 1,141
Bladder cancer: Epidemiology, staging and grading, and diagnosis
Kirkali, Z., Chan, T., Manoharan, M., Algaba, F., Busch, C., Cheng, L., Kiemeney, L., Kriegmair, M., Montironi, R., Murphy, W. M., et al. (2005) · Urology · doi:10.1016/j.urology.2005.07.062 · Cited by 1,074
The global burden of urinary bladder cancer: an update
Richters, A., Aben, K. K. H., & Kiemeney, L. A. L. M. (2020) · World Journal of Urology · doi:10.1007/s00345-019-02984-4 · Cited by 958
Familial Risk and Heritability of Cancer Among Twins in Nordic Countries
Mucci, L. A., Hjelmborg, J. B., Harris, J. R., Czene, K., Havelick, D. J., Scheike, T., Graff, R. E., Holst, K., Möller, S., Unger, R. H., et al. (2016) · JAMA · doi:10.1001/jama.2015.17703 · Cited by 938
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
Chang, S. S., Bochner, B. H., Chou, R., Dreicer, R., Kamat, A. M., Lerner, S. P., Lotan, Y., Meeks, J. J., Michalski, J. M., Morgan, T. M., et al. (2017) · Journal of Urology · doi:10.1016/j.juro.2017.04.086 · Cited by 938
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869
Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
Cumberbatch, M. G. K., Jubber, I., Black, P. C., Esperto, F., Figueroa, J. D., Kamat, A. M., Kiemeney, L., Lotan, Y., Pang, K., Silverman, D. T., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.001 · Cited by 820
SYLVESTER, R. J., OOSTERLINCK, W., & van der MEIJDEN, A. P. M. (2004) · Journal of Urology · doi:10.1097/01.ju.0000125486.92260.b2 · Cited by 743
Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W. K., Dreicer, R., Vogelzang, N., Sternberg, C. N., Bajorin, D. F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8433 · Cited by 705
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
Dobruch, J., Daneshmand, S., Fisch, M., Lotan, Y., Noon, A. P., Resnick, M. J., Shariat, S. F., Zlotta, A. R., & Boorjian, S. A. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.037 · Cited by 673
Rosenberg, J. E., O’Donnell, P. H., Balar, A. V., McGregor, B. A., Heath, E. I., Yu, E. Y., Galsky, M. D., Hahn, N. M., Gartner, E. M., Pinelli, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01140 · Cited by 642
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Christensen, E., Birkenkamp-Demtröder, K., Sethi, H., Shchegrova, S., Salari, R., Nordentoft, I., Wu, H.-T., Knudsen, M., Lamy, P., Lindskrog, S. V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02052 · Cited by 556
Sternberg, C. N., de Mulder, P., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, J. A., Spina, M., van Groeningen, C. J., Duclos, B., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.032 · Cited by 542
Burger, M., Grossman, H. B., Droller, M. J., Schmidbauer, J., Hermann, G. G., Drăgoescu, O. P., Ray, E. R., Fradet, Y., Karl, A., Burgués, J. P., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.03.059 · Cited by 480
Yin, M., Joshi, M., Meijer, R. P., Glantz, M., Holder, S., Harvey, H. A., Kaag, M., Fransen van de Putte, E. E., Horenblas, S., & Drabick, J. J. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0440 · Cited by 474
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
Pettenati, C., & Ingersoll, M. A. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0055-4 · Cited by 457
Sternberg, C. N., Skoneczna, I., Kerst, J. M., Albers, P., Fossa, S. D., Agerbaek, M., Dumez, H., de Santis, M., Théodore, C., Leahy, M. G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71160-x · Cited by 389
Brausi, M., Oddens, J., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., Gontero, P., Turkeri, L., Marreaud, S., Collette, S., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.07.021 · Cited by 389
SYLVESTER, R. J., van der MEIJDEN, A. P. M., WITJES, J. A., & KURTH, K. (2005) · Journal of Urology · doi:10.1097/01.ju.0000162059.64886.1c · Cited by 385
van den Bosch, S., & Alfred Witjes, J. (2011) · European Urology · doi:10.1016/j.eururo.2011.05.045 · Cited by 382
The effect of age and gender on bladder cancer: a critical review of the literature
Shariat, S. F., Sfakianos, J. P., Droller, M. J., Karakiewicz, P. I., Meryn, S., & Bochner, B. H. (2010) · BJU International · doi:10.1111/j.1464-410x.2009.09076.x · Cited by 371
Gschwend, J. E., Heck, M. M., Lehmann, J., Rubben, H., Albers, P., Wolff, J. M., Frohneberg, D. H., de Geeter, P., Heidenreich, A., Kälble, T., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.047 · Cited by 359
Steinberg, G. D., Bahnson, R., Brosman, S. A., MIDDLETON, R., Wajsman, Z., Wehle, M. J., & THE VALRUBICIN STUDY GROUP (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67799-3 · Cited by 357
Ploussard, G., Daneshmand, S., Efstathiou, J. A., Herr, H. W., James, N. D., Rödel, C. M., Shariat, S. F., Shipley, W. U., Sternberg, C. N., Thalmann, G. N., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.038 · Cited by 355
Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review
Cumberbatch, M. G. K., Foerster, B., Catto, J. W. F., Kamat, A. M., Kassouf, W., Jubber, I., Shariat, S. F., Sylvester, R. J., & Gontero, P. (2018) · European Urology · doi:10.1016/j.eururo.2018.02.014 · Cited by 343
Second Cancers Among 104760 Survivors of Cervical Cancer: Evaluation of Long-Term Risk
Chaturvedi, A. K., Engels, E. A., Gilbert, E. S., Chen, B. E., Storm, H., Lynch, C. F., Hall, P., Langmark, F., Pukkala, E., Kaijser, M., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm201 · Cited by 341
Necchi, A., Raggi, D., Gallina, A., Madison, R., Colecchia, M., Lucianò, R., Montironi, R., Giannatempo, P., Farè, E., Pederzoli, F., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.10.026 · Cited by 325
Nieuwenhuijzen, J. A., de Vries, R. R., Bex, A., van der Poel, H. G., Meinhardt, W., Antonini, N. F., & Horenblas, S. (2007) · European Urology · doi:10.1016/j.eururo.2007.09.008 · Cited by 325
Hurst, C. D., Alder, O., Platt, F. M., Droop, A., Stead, L. F., Burns, J. E., Burghel, G. J., Jain, S., Klimczak, L. J., Lindsay, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.005 · Cited by 311
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Zargar, H., Espiritu, P. N., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L.-M., Cookson, M. S., Jacobsen, N.-E., Gandhi, N. M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.007 · Cited by 294
Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis
Wallis, C. J. D., Mahar, A. L., Choo, R., Herschorn, S., Kodama, R. T., Shah, P. S., Danjoux, C., Narod, S. A., & Nam, R. K. (2016) · BMJ · doi:10.1136/bmj.i851 · Cited by 271
Dash, A., Pettus, J. A., Herr, H. W., Bochner, B. H., Dalbagni, G., Donat, S. M., Russo, P., Boyle, M. G., Milowsky, M. I., & Bajorin, D. F. (2008) · Cancer · doi:10.1002/cncr.23848 · Cited by 258
Microhematuria: AUA/SUFU Guideline
Barocas, D. A., Boorjian, S. A., Alvarez, R. D., Downs, T. M., Gross, C. P., Hamilton, B. D., Kobashi, K. C., Lipman, R. R., Lotan, Y., Ng, C. K., et al. (2020) · Journal of Urology · doi:10.1097/ju.0000000000001297 · Cited by 250
Messing, E. M., Tangen, C. M., Lerner, S. P., Sahasrabudhe, D. M., Koppie, T. M., Wood, D. P., Mack, P. C., Svatek, R. S., Evans, C. P., Hafez, K. S., et al. (2018) · JAMA · doi:10.1001/jama.2018.4657 · Cited by 244
What Is the Significance of Variant Histology in Urothelial Carcinoma?
Lobo, N., Shariat, S. F., Guo, C. C., Fernandez, M. I., Kassouf, W., Choudhury, A., Gao, J., Williams, S. B., Galsky, M. D., Taylor, J. A., et al. (2020) · European Urology Focus · doi:10.1016/j.euf.2019.09.003 · Cited by 243
EDWARDS, T. J., Dickinson, A., Natale, S., Gosling, J., & McGrath, J. S. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.05976.x · Cited by 242
Robinson, B. D., Vlachostergios, P. J., Bhinder, B., Liu, W., Li, K., Moss, T. J., Bareja, R., Park, K., Tavassoli, P., Cyrta, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10873-y · Cited by 214
Steinberg, R. L., Thomas, L. J., Brooks, N. A., Mott, S. L., Vitale, A., Crump, T., Rao, M. Y., Daniels, M. J., Wang, J., Nagaraju, S., et al. (2019) · The Journal of Urology · doi:10.1097/ju.0000000000000688 · Cited by 206
Shariat, S. F., Milowsky, M., & Droller, M. J. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.07.020 · Cited by 205
Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide
Knight, A., Askling, J., Granath, F., Sparen, P., & Ekbom, A. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.019125 · Cited by 204
A Critical Analysis of Perioperative Mortality From Radical Cystectomy
Quek, M. L., Stein, J. P., Daneshmand, S., Miranda, G., Thangathurai, D., Roffey, P., Skinner, E. C., Lieskovsky, G., & Skinner, D. G. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(05)00421-0 · Cited by 164
Cancer Susceptibility Mutations in Patients With Urothelial Malignancies
Carlo, M. I., Ravichandran, V., Srinavasan, P., Bandlamudi, C., Kemel, Y. M., Ceyhan‐Birsoy, O., Mukherjee, S., Mandelker, D. L., Chaim, J. L., Knežević, A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01395 · Cited by 149
Immunotherapy for the Treatment of Urothelial Carcinoma
Donin, N. M., Lenis, A. T., Holden, S., Drakaki, A., Pantuck, A. J., Belldegrun, A. S., & Chamie, K. (2016) · The Journal of Urology · doi:10.1016/j.juro.2016.02.3005 · Cited by 137
Self-citationBalar, A. V., Kulkarni, G. S., Uchio, E., Boormans, J. L., Mourey, L., Krieger, L. E. M., Singer, E. A., Bajorin, D. F., Kamat, A. M., Grivas, P. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.350 · Cited by 125
Ritch, C. R., Velasquez, M. C., Kwon, D., Becerra, M. F., Soodana‐Prakash, N., Atluri, V. S., Almengo, K., Alameddine, M., Kineish, O., Kava, B., et al. (2019) · The Journal of Urology · doi:10.1097/ju.0000000000000593 · Cited by 114
Rosenberg, J. E., Flaig, T. W., Friedlander, T. W., Milowsky, M. I., Srinivas, S., Petrylak, D. P., Merchan, J. R., Bilen, M. A., Carret, A., Yuan, N., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.6_suppl.441 · Cited by 114
Knoedler, J., Boorjian, S. A., Kim, S. P., Weight, C., Thapa, P. B., Tarrell, R. F., Cheville, J. C., & Frank, I. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.06.029 · Cited by 108
Moschini, M., Zaffuto, E., Karakiewicz, P. I., D’Andrea, D., Foerster, B., Abufaraj, M. M., Soria, F., Mattei, A., Montorsi, F., Briganti, A., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.034 · Cited by 108
Cahn, D. B., Handorf, E. A., Ghiraldi, E. M., Ristau, B. T., Geynisman, D. M., Churilla, T. M., Horwitz, E. M., Sobczak, M. L., Chen, D. Y. T., Viterbo, R., et al. (2017) · Cancer · doi:10.1002/cncr.30900 · Cited by 106
Williams, S. B., Shan, Y., Jazzar, U., Mehta, H. B., Baillargeon, J., Huo, J. S., Senagore, A. J., Orihuela, E., Tyler, D. S., Swanson, T. A., et al. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2018.1680 · Cited by 102
Luo, C., Huang, B., Wu, Y., Chen, J., & Chen, L. (2020) · European Radiology · doi:10.1007/s00330-020-06802-z · Cited by 99
Metabolic and functional consequences of urinary reconstruction with bowel
Gerharz, E. W., Turner, W. H., Kälble, T., & Woodhouse, C. R. J. (2003) · British Journal of Urology · doi:10.1046/j.1464-410x.2003.04000.x · Cited by 99
Racial differences in Urinary Bladder Cancer in the United States
Wang, Y., Chang, Q., & Li, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-29987-2 · Cited by 88
Understanding Urogenital Schistosomiasis-Related Bladder Cancer: An Update
Ishida, K., & Hsieh, M. H. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00223 · Cited by 88
Zhang, Z., Fan, W., Deng, Q., Tang, S., Wang, P., Xu, P., Wang, J., & Yu, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18521 · Cited by 83
Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer
Hu, M., Jacobs, B. L., Montgomery, J. S., He, C., Ye, J., Zhang, Y., Brathwaite, J., Morgan, T. M., Hafez, K. S., Weizer, A. Z., et al. (2014) · Cancer · doi:10.1002/cncr.28586 · Cited by 81
Özkan, T. A. (2015) · Journal of Urological Surgery · doi:10.4274/jus.2015.01.004 · Cited by 78
Xiong, Y., Li, J., Ma, S., Ge, J., Zhou, L., Li, D., & Chen, Q. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170819 · Cited by 77
The characteristics of bladder cancer after radiotherapy for prostate cancer
Abern, M. R., Dude, A., Tsivian, M., & Coogan, C. L. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.04.006 · Cited by 70
Perivesical fat necrosis after adjuvant intravesical chemotherapy
Doherty, Trendell‐Smith, Stirling, Rogers, & Bellringer (1999) · British Journal of Urology · doi:10.1046/j.1464-410x.1999.00951.x · Cited by 57
Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin
Bandari, J., Maganty, A., Macleod, L. C., & Davies, B. J. (2018) · European Urology Focus · doi:10.1016/j.euf.2018.06.018 · Cited by 55
Gild, P., Wankowicz, S. A. M., Sood, A., von Landenberg, N., Friedlander, D. F., Alanee, S. R., Chun, F. K. ‐., Fisch, M., Menon, M., Trinh, Q., et al. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.07.012 · Cited by 54
Warschkow, R., Güller, U., Cerny, T., Schmied, B. M., Plaßwilm, L., & Putora, P. M. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.02.007 · Cited by 53
Westergren, D.-O., Gårdmark, T., Lindhagen, L., Chau, A., & Malmström, P. (2019) · The Journal of Urology · doi:10.1097/ju.0000000000000350 · Cited by 53
Advances in risk stratification of bladder cancer to guide personalized medicine
Matulay, J. T., & Kamat, A. M. (2018) · F1000Research · doi:10.12688/f1000research.14903.1 · Cited by 50
Antibody-Drug Conjugates in Urothelial Carcinomas
Sarfaty, M., & Rosenberg, J. E. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0879-y · Cited by 48
Quality of diagnostic staging in patients with bladder cancer: A process‐outcomes link
Chamie, K., Ballon-Landa, E. C., Bassett, J. C., Daskivich, T. J., Leventhal, M., Deapen, D., & Litwin, M. S. (2014) · Cancer · doi:10.1002/cncr.29071 · Cited by 47
Self-citationLerner, S. P., Bajorin, D. F., Dinney, C. P., Efstathiou, J. A., Groshen, S. G., Hahn, N. M., Hansel, D. E., Kwiatkowski, D. J., O’Donnell, M. A., Rosenberg, J. E., et al. (2016) · Bladder Cancer · doi:10.3233/blc-160053 · Cited by 44
Lynch syndrome and urologic malignancies: a contemporary review
Lim, A. H., Rao, P., & Matin, S. F. (2019) · Current Opinion in Urology · doi:10.1097/mou.0000000000000639 · Cited by 39
Diagnostic biomarkers in non-muscle invasive bladder cancer
Faiena, I., Rosser, C. J., Chamie, K., & Furuya, H. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2567-1 · Cited by 33
Self-citationSystematic Review: An Update on the Spectrum of Urological Malignancies in Lynch Syndrome
Huang, D. C., Matin, S. F., Lawrentschuk, N., & Morgan Rouprêt, A. (2018) · Bladder Cancer · doi:10.3233/blc-180180 · Cited by 31
Trends in urinary diversion after radical cystectomy for urothelial carcinoma
Bachour, K., Faiena, I., Salmasi, A., Lenis, A. T., Johnson, D. C., Pooli, A. H., Drakaki, A., Pantuck, A. J., & Chamie, K. (2018) · World Journal of Urology · doi:10.1007/s00345-017-2169-3 · Cited by 30
Self-citationTagawa, S. T., Balar, A. V., Petrylak, D. P., Grivas, P. D., Agarwal, N., Sternberg, C. N., Hong, Q., Gladden, A., Kanwal, C., Siemon-Hryczyk, P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.049 · Cited by 29
Golla, V., Lenis, A. T., Faiena, I., & Chamie, K. (2019) · PubMed · Cited by 23
Self-citationFreshwater, T., Li, H., Valiathan, C., Li, M., Perini, R. F., Bracco, O. L., Frenkl, T. L., & O’Keefe, S. J. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000585 · Cited by 10
118 Does the extent of lymphadenectomy impact survival after radical cystectomy: A systematic review
Bruins, H. M., Hernández, V., Veskimäe, E., Imamura, M., Lam, T. B. L., Neuberger, M., Dahm, P., van der Heijden, A. G., Comperat, E., Cowan, N. C., et al. (2014) · European Urology Supplements · doi:10.1016/s1569-9056(14)60119-6 · Cited by 2
Research works printed but not linked: 3
- Chang, 2017, Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline., J Urol., 198, 552, 10.1016/j.juro.2017.04.086 · DOI · Paper page
- von der Maase, 2000, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study., J Clin Oncol, 18, 3068, 10.1200/jco.2000.18.17.3068 · DOI · Paper page
- Oxford Centre for Evidence-based Medicine: levels of evidence. Updated March 2009. Accessed June 28, 2020. https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
Cited by
Trained immunity — basic concepts and contributions to immunopathology
Ochando, J., Mulder, W. J. M., Madsen, J. C., Netea, M. G., & Duivenvoorden, R. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00633-5 · Cited by 453
Naringenin: A potential flavonoid phytochemical for cancer therapy
Motallebi, M., Bhia, M., Rajani, H. F., Bhia, I., Tabarraei, H., Mohammadkhani, N., Pereira-Silva, M., Kasaii, M. S., Nouri-Majd, S., Mueller, A.-L., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120752 · Cited by 328
Cancer treatment and survivorship statistics, 2025
Wagle, N. S., Nogueira, L., Devasia, T. P., Mariotto, A. B., Yabroff, K. R., Islami, F., Jemal, A., Alteri, R., Ganz, P. A., & Siegel, R. L. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.70011 · Cited by 261
Li, F., Zhang, H., Huang, Y., Li, D., Zheng, Z., Xie, K., Cao, C., Wang, Q., Zhao, X., Huang, Z., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101059 · Cited by 236
Xie, B., Lin, J., Chen, X., Zhou, X., Zhang, Y., Fan, M., Xiang, J., He, N., Hu, Z., & Wang, F. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01856-1 · Cited by 216
Metadata
- Authors
- Lenis, A. T., Lec, P. M., Chamie, K., & MSHS, M.
- Affiliations
- University of California, Los Angeles (US)
- Institute of Urologic Oncology (IUO), Department of Urology, David Geffen School of Medicine, University of California, Los Angeles
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-11-17
- Volume
- 324
- Issue
- 19
- Pages
- 1980
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3102493364
- Cited by
- 2,051
- References
- 97
- Citations by year
- 2026: 270 · 2025: 311 · 2024: 491 · 2023: 436 · 2022: 408 · 2021: 134
- FWCI
- 49.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
- Keywords
- bladder cancer, non-muscle-invasive bladder cancer, muscle-invasive bladder cancer, hematuria, cystoscopy, intravesical therapy, BCG vaccine, radical cystectomy, trimodality therapy, immunotherapy, immune checkpoint inhibitors, targeted therapy, antibody-drug conjugates, risk classification, recurrence, molecular genetics
- MeSH terms
- Administration, Intravesical, Antineoplastic Agents, BCG Vaccine, Urinary Bladder, Urinary Bladder Neoplasms, Combined Modality Therapy, Cystoscopy, Female, Humans, Immunotherapy, Male, Mutation, Neoplasm Invasiveness, Risk Factors, Cystectomy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.